Recent Quotes (30 days)

You have no recent quotes
chg | %

Bio Therapeutic Drugs News

Showing stories 1 - 10 of about 70   
Risk Malaise Alert in Option Market: Gilead Sciences Inc Implied Price Swing ...
Before we dive into any analysis we simply note that Gilead Sciences Inc (NASDAQ:GILD) risk is actually priced pretty low by the option market as of right now.
Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter
The big biotech's fourth-quarter update sounded a lot like its third-quarter results, with continued HCV sales declines. Keith Speights.
Gilead Sciences Inc. Q4 Profit Retreats  Nasdaq
Gilead Sciences, Inc. (GILD) Shares Slide on Weak Outlook  Investorplace.com
Orbimed Advisors Llc Buys Regeneron Pharmaceuticals Inc, Amicus Therapeutics ...
New York, NY, based Investment company Orbimed Advisors Llc buys Regeneron Pharmaceuticals Inc, Amicus Therapeutics Inc, Loxo Oncology Inc, Rhythm Pharmaceuticals Inc, scPharmaceuticals Inc, DaVita Inc, Nevro Corp, ACADIA Pharmaceuticals Inc, Arsanis ...
Regeneron Pharmaceuticals Inc. (REGN) Rises 2.55% for February 23
Among the biggest risers on the S&P 500 on Friday February 23 was Regeneron Pharmaceuticals Inc. ($REGN), popping some 2.55% to a price of $323.86 a share with some 672,175 shares trading hands.
Sumitomo Mitsui Asset Management Company LTD Cuts Stake in Regeneron ...  The Ledger Gazette
Regeneron Pharmaceuticals Inc (REGN) Director Joseph L. Goldstein Sells 1000 ...  StockNewsTimes
Some Thoughts On The Continued Negative Media For Regeneron
Regeneron, with a productive pipeline and one of the world's largest-selling drugs in Eylea, has been dropping sharply lately.
Form 4 GILEAD SCIENCES INC For: Feb 15 Filed by: BISCHOFBERGER NORBERT W
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person *. BISCHOFBERGER NORBERT W. (Last), (First), (Middle). GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE ...
The Case for and Against Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $157.59, down from yesterday's close by -0.19%.
Vertex Pharmaceuticals Incorporated (VRTX) SVP Sells $646316.33 in Stock  The Ledger Gazette
Choosing Between Hot Stocks: Exelixis, Inc. (EXEL), Vertex Pharmaceuticals ...  StockNewsGazette
How to Trade these Stock After an unavoidable Selloff: Gilead Sciences, Inc ...
Gilead Sciences, Inc. (NASDAQ:GILD) market capitalization at present is $104.78B at the rate of $79.40 a share. The firm's price-to-sales ratio was noted 4.04 in contrast with an overall industry average of 135.24.
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Dearborn Partners LLC  Dispatch Tribunal
Latest Analysts Research Reports About Exelon Corporation (EXC), Gilead ...  Post Analyst
Why to Keeping Eye on Bristol-Myers Squibb Company (BMY), Gilead Sciences, Inc ...
Bristol-Myers Squibb Company (NYSE:BMY) plunged -1.22% with the closing price of $66.53. The overall volume in the last trading session was 7.01 million shares.
Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
Paris - February 8, 2018 - Sanofi announced today that on February 7, 2018 it commenced a tender offer (the "Offer") to acquire all of the outstanding shares of common stock of Bioverativ, Inc. ("Bioverativ") for $105 per share in cash (the "Offer ...
The Top Three Holders Of Bioverativ Inc. (BIVV)  Post Analyst